The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nagayama, Y.
Right arrow Articles by Rapoport, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nagayama, Y.
Right arrow Articles by Rapoport, B.
The Journal of Immunology, 2004, 173: 2167-2173.
Copyright © 2004 by The American Association of Immunologists

Schistosoma mansoni and {alpha}-Galactosylceramide: Prophylactic Effect of Th1 Immune Suppression in a Mouse Model of Graves’ Hyperthyroidism

Yuji Nagayama1,*,{dagger}, Kanji Watanabe{ddagger}, Masami Niwa{dagger}, Sandra M. McLachlan§ and Basil Rapoport§

* Department of Medical Gene Technology, Atomic Bomb Disease Institute, Graduate School of Biomedical Sciences, {dagger} Department of Pharmacology, Graduate School of Biomedical Sciences, and {ddagger} Department of Parasitology, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan; and § Autoimmune Disease Unit, Cedars-Sinai Research Institute and School of Medicine, University of California, Los Angeles, CA 90048


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Graves’ hyperthyroidism, an organ-specific autoimmune disease mediated by stimulatory thyrotropin receptor (TSHR) autoantibodies, has been considered a Th2-dominant disease. However, recent data with mouse Graves’ models are conflicting. For example, we recently demonstrated that injection of BALB/c mice with adenovirus coding the TSHR induced Graves’ hyperthyroidism characterized by mixed Th1 and Th2 immune responses against the TSHR, and that transient coexpression of the Th2 cytokine IL-4 by adenovirus skewed Ag-specific immune response toward Th2 and suppressed disease induction. To gain further insight into the relationship between immune polarization and Graves’ disease, we evaluated the effect of Th2 immune polarization by helminth Schistosoma mansoni infection and {alpha}-galactosylceramide ({alpha}-GalCer), both known to bias the systemic immune response to Th2, on Graves’ disease. S. mansoni infection first induced mixed Th1 and Th2 immune responses to soluble worm Ags, followed by a Th2 response to soluble egg Ags. Prior infection with S. mansoni suppressed the Th1-type anti-TSHR immune response, as demonstrated by impaired Ag-specific IFN-{gamma} secretion of splenocytes and decreased titers of IgG2a subclass anti-TSHR Abs, and also prevented disease development. Similarly, {alpha}-GalCer suppressed Ag-specific splenocyte secretion of IFN-{gamma} and prevented disease induction. However, once the anti-TSHR immune response was fully induced, S. mansoni or {alpha}-GalCer was ineffective in curing disease. These data support the Th1 theory in Graves’ disease and indicate that suppression of the Th1-type immune response at the time of Ag priming may be crucial for inhibiting the pathogenic anti-TSHR immune response.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Graves’ disease is an organ-specific autoimmune disease in which stimulatory thyrotropin receptor (TSHR)2 autoantibodies (thyroid-stimulating Abs (TSAb)) cause hyperthyroidism and diffuse goiter (1). Understanding the pathogenesis of Graves’ disease has been aided by the development of animal models. For instance, in our mouse model involving repeated i.m. injection of adenovirus coding the TSHR (Ad-TSHR) (2), the TSHR Abs induced are of both IgG1 and IgG2a subclasses, and splenocytes produce the Th1 cytokine IFN-{gamma} in response to in vitro stimulation with TSHR Ag (3). Similarly, Prabhakar et al. (4) have found both IgG1 and IgG2a of TSHR Abs and Ag-specific splenocyte secretion of IFN-{gamma} and the Th2 cytokine IL-4 after injecting M12 B lymphoma cells expressing the TSHR. These data indicate the involvement of both Th1 and Th2 immune responses in the pathogenesis of Graves’ disease, at least in animal models. Furthermore, we have also shown that transient coexpression of TSHR and IL-4 by adenovirus induces Th2 deviation of the anti-TSHR immune response and suppresses disease induction. In contrast, coinjection of adenovirus coding IL-12 deviates the anti-TSHR immune response to Th1 without affecting disease incidence (3). Thus, Th2 polarization may be beneficial for the control of Graves’ disease. However, because of the transient nature of transgene expression by adenovirus, our results imply the suppressive effect of transiently overexpressed exogenous IL-4 on disease development. We were curious to know the effect of more physiological, long-lasting Th2 immune deviation on Graves’ disease. We therefore evaluated in this study the effect of Th2 immune deviation by {alpha}-galactosylceramide ({alpha}-GalCer) and infection with helminth Schistosoma mansoni on Graves’ disease in our mouse model.

{alpha}-GalCer, a marine-sponge derived glycolipid, is an agonistic ligand for invariant NKT cells (5). NKT cells represent a unique immune cell lineage that have characteristics of both NK and T cells, expressing NK cell markers such as NK1.1 and a highly restricted TCR repertoire (V{alpha}14J{alpha}281V{beta}8.2 in mice and V{alpha}24J{alpha}QV{beta}11 in humans) (6, 7). These cells have a unique Ag recognition system, in that they recognize glycolipid Ags in conjunction with the nonpolymorphic, nonclassical major MHC class I-like molecule CD1d expressed on most hemopoietic cells. Although a natural ligand(s) for CD1d has not yet been identified, {alpha}-GalCer has recently been shown to be a potent stimulator of both human and mouse NKT cells (5). {alpha}-GalCer stimulates NKT cells to rapidly produce both Th1 and Th2 cytokines, but at a later time point and with repeated doses, {alpha}-GalCer promotes the development of a Th2 immune response (8, 9). NKT cells regulate numerous immune responses during innate and adaptive immunities and are reported to influence the pathogenesis of Th1-dominant autoimmune diseases. For example, a reduced number and/or impaired function of NKT cells are demonstrated in several autoimmune diseases, such as type I diabetes, experimental autoimmune encephalitis (EAE)/multiple sclerosis, and lupus (10, 11, 12, 13, 14, 15, 16). Passive transfer of NKT cells or transgenic expression of V{alpha}14J{alpha}281 have previously been shown to suppress diabetes or EAE (17, 18). Prevention and/or cure of diabetes, EAE, and colitis with {alpha}-GalCer have also been demonstrated in mouse models (19, 20, 21, 22, 23, 24, 25, 26, 27). Conversely, CD1d-deficient NOD mice have an earlier disease onset, increased disease penetrance, and more severe disease (22, 23, 28).

Helminth infections have potent systemic immunomodulatory effects on the host immune system directed to other infectious agents and noninfectious Ags (29). For example, S. mansoni infection is initiated by penetration of the skin by waterborne cercariae that migrate into the bloodstream and finally arrive in the hepatic portal system, where the differentiated male and female mate. At approximately the fifth week postinfection (p.i.), the mature female worms begin to produce large numbers of eggs, which lodge in the liver and intestinal tissue where they induce a granulomatous response that results in the major pathologic manifestations of the disease (30). The immune response to S. mansoni is reportedly initially a Th1 phenotype against the larval and adult worms, followed by a Th2 response to the parasite eggs 6–8 wk p.i (31, 32). Thus, a sustained Th2-dominant immune response to S. mansoni egg Ags probably creates a cytokine environment that induces a Th1 to Th2 shift of the immune responses to unrelated Ags (33, 34, 35). In addition, of interest, S. mansoni eggs and worms express a variety of glycoconjugates, including GalCer (36), suggesting that the effect of S. mansoni infection may at least partly be mediated by NKT cells. S. mansoni infection has been shown to suppress Th1 autoimmune diseases, including type 1 diabetes (37, 38), EAE (39), and arthritis (40).

We show in this study that suppression of the Th1-type anti-TSHR immune response by prior infection with S. mansoni or {alpha}-GalCer at the time of Ag priming prevents the development of Graves’ hyperthyroidism, but after activation of an anti-TSHR immune response cannot cure disease, indicating a difficulty in reverting an already established pathogenic anti-TSHR immune response by such immunological interventions.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Immunization with Ad-TSHR

Nonreplicative recombinant adenovirus expressing the human TSHR (Ad-TSHR) has previously been described (2). Amplification, purification, and determination of the viral particle concentration were performed as previously described (2). Female BALB/c mice (6 wk old; Charles River Laboratories, Tokyo, Japan) were injected in the quadriceps with 50 µl of PBS containing 1011 particles of Ad-TSHR three times at 3-wk intervals as previously described (2). Blood was drawn at the time points indicated. All experiments were conducted in accordance with the principles and procedures outlined in the Guidelines for the Care and Use of Laboratory Animals at Nagasaki University. Mice were kept under specific pathogen-free conditions through the experiments.

{alpha}-GalCer treatment

{alpha}-GalCer was provided by Kirin Brewery (Gunma, Japan) and was dissolved in a vehicle of H2O containing 0.05% polysorbate 20 (5). In a prophylactic setting, mice were injected i.p. with 100 µg/kg (~2 µg/mouse) {alpha}-GalCer or vehicle at the time of each immunization and on days 3 and 7 postimmunization. In a therapeutic setting, i.p. injection of {alpha}-GalCer (300 µg/kg; ~6 µg/mouse, twice a week) was initiated 1 wk after the third immunization with Ad-TSHR and was continued for 7 wk.

Infection with S. mansoni and immunization with soluble worm Ag (SWA) and soluble egg Ag (SEA) proteins

The maintenance and production of S. mansoni have been previously described (41). SWA and SEA proteins were prepared from homogenized adult worms and eggs, respectively, using previously described procedures (42, 43). Mice were infected with S. mansoni by percutaneous exposure of the abdomen to 15 cercariae. Successful infection of S. mansoni was monitored by ELISA against SWA and SEA proteins (see below). Alternatively, mice were i.p. injected with 50 µg/mouse of SWA or SEA proteins on days –7, –4, and 0 of each immunization with AdTSHR.

Thyroxine (T4), TSAb, and TSH binding inhibiting Ab (TBIAb) measurements

Total serum T4 was measured with an RIA kit (RIA-gnost tT4; Nippon Schering, Osaka, Japan). The normal range was defined as the mean ± 3 SD of control untreated mice. TSAb activities in mouse sera were measured with FRTL5 cells (2). The cells seeded at 3 x 104 cells/well in a 96-well plate were incubated in 50 µl of hypotonic HBSS containing 0.5 mM isobutylmethylxanthine, 20 mM HEPES, 0.25% BSA, and 5 µl of serum for 2 h at 37 C. cAMP released into the medium was measured with a cAMP RIA kit (Yamasa, Tokyo, Japan). A value >150% of that in control mice was judged positive. TBIAb values were determined with a TRAb kit (BRAHMS Diagnostica, Berlin, Germany) using 10 µl of serum. A value >15% inhibition of control binding was judged positive.

ELISA for Abs to TSHR, SWA, and SEA

ELISA wells were coated overnight with 100 µl of TSHR-289 protein (1 µg/ml) (44), SEA (10 µg/ml), or SWA (10 µg/ml) and incubated with mouse serum (1/100 to 1/1000 dilutions). After incubation with HRP-conjugated anti-mouse IgG (diluted 3000-fold; A3673; Sigma-Aldrich, St. Louis, MO), or subclass-specific anti-mouse IgG1 and IgG2a (diluted 1000- and 1500-fold; X56 and R19-15; BD Pharmingen, San Diego, CA), color was developed using orthophenylene diamine and H2O2 as substrate, and OD was read at 492 nm.

Cytokine assays

Splenocytes were cultured (triplicate aliquots) at 5 x 105 cells/well in a 96-well, round-bottom plate in the presence or the absence of TSHR-289 protein (5 µg/ml), {alpha}-GalCer (50 ng/ml), or Con A (5 µg/ml). Five days later, the concentrations of IFN-{gamma}, IL-4, and IL-10 in the medium were determined with ELISA kits (BioSource International, Camarillo, CA). Cytokine production was expressed as picograms per milliliter using standard curves of recombinant mouse cytokines.

Statistical analysis

Levels of Abs and cytokines were analyzed by Mann-Whitney U test. The incidence of disease was evaluated by {chi}2 test. A value of p < 0.05 was considered significant.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Effect of {alpha}-GalCer on Graves’ disease induction

We first tested the ability of {alpha}-GalCer to stimulate NKT cells in BALB/c mice to produce cytokines and to modulate adaptive immune responses. A single i.p. injection of 100 µg/kg {alpha}-GalCer induced a rapid increase in serum IL-4 and a delayed elevation in IFN-{gamma} (Fig. 1A). However, prior in vivo injections of {alpha}-GalCer on days –10, –7, and –3 suppressed {alpha}-GalCer-induced IFN-{gamma} elevation, but not a rise in IL-4 (Fig. 1B). These data clearly show that a single injection of {alpha}-GalCer stimulated secretion of both Th1 and Th2 cytokines, whereas repeated injections induced only Th2 cytokine secretion.



View larger version (30K):
[in this window]
[in a new window]
  		FIGURE 1. In vivo production of IFN-{gamma} and IL-4 in mice primed with {alpha}-GalCer. Mice pretreated with i.p. injection of vehicle (A) or 100 µg/kg {alpha}-GalCer on days –10, –7, and –3 (B) were i.p. injected with 100 µg/kg {alpha}-GalCer and were bled at the time points indicated. Serum IFN-{gamma} and IL-4 were measured by ELISA. Data are the mean ± SE of three mice per group and are expressed as picograms per milliliter.

 
The next experiments were conducted with in vitro cultured splenocytes. In vitro stimulation of splenocytes from naive mice with {alpha}-GalCer or Con A produced both IFN-{gamma} and IL-4 (Fig. 2). In contrast, the splenocytes from {alpha}-GalCer-primed mice on days –10, –7, and –3 secreted IL-4, but failed to produce IFN-{gamma} in response to in vitro stimulation with {alpha}-GalCer (p < 0.001), although in vivo priming with {alpha}-GalCer did not alter cytokine responses to Con A. These data are consistent with the above-mentioned in vivo data, indicating that repeated injection of {alpha}-GalCer selectively suppressed {alpha}-GalCer-induced splenocyte secretion of the Th1 cytokine.



View larger version (31K):
[in this window]
[in a new window]
  		FIGURE 2. In vitro secretion of IFN-{gamma} and IL-4 from splenocytes of mice immunized with Ad-TSHR and/or {alpha}-GalCer. Splenocytes were prepared from mice injected with vehicle or 100 µg/kg {alpha}-GalCer on days –10, –7, and –3 and/or with Ad-TSHR on day –10 and were stimulated in vitro with 50 ng/ml {alpha}-GalCer, 5 µg/ml TSHR-289 protein, or 5 µg/ml Con A for 5 days. IFN-{gamma} (A) and IL-4 (B) levels in the culture supernatants were measured by ELISA. Data are the means ± SD of three mice per group and are expressed as picograms per milliliter. *, Significant difference by Mann-Whitney U test.

 
Cytokine production from splenocytes of mice immunized with Ad-TSHR alone or in combination with {alpha}-GalCer was also evaluated. As we have previously shown (3), splenocytes from mice immunized with Ad-TSHR produced IFN-{gamma} in response to in vitro stimulation with TSHR-289 protein. This Ag-specific splenocyte secretion of IFN-{gamma} was almost completely suppressed by prior in vivo injection of {alpha}-GalCer (Fig. 2; p < 0.001).

We then examined the prophylactic effect of {alpha}-GalCer on Graves’ disease induction. Mice were injected with Ad-TSHR alone or in combination with {alpha}-GalCer (100 µg/kg) on the day of immunization and 3 and 7 days later in each immunization. Serum T4 was measured 2 and 8 wk after the last immunization. Elevated T4 levels (greater than the mean + 3 SD of control mice) were observed in 40% (4 of 10) and 70% (7 of 10) of Ad-TSHR-immunized mice (TSHR group) at these two time points vs 7% (1 of 15) and 12% (2 of 15) in Ad-TSHR-immunized and {alpha}-GalCer-primed mice (TSHR plus {alpha}-GalCer group; p = 0.04 and p < 0.001; Fig. 3, A and B).



View larger version (30K):
[in this window]
[in a new window]
  		FIGURE 3. T4, TSAb, and TBIAb values in mice immunized with Ad-TSHR alone or in combination with {alpha}-GalCer in a prophylactic setting. T4 were determined 2 and 8 wk (A and B), and TSAb and TBIAb were measured 8 wk (C and D) after the third immunization. Data are the means of duplicate determinations. {circ}, Euthyroid mice; •, hyperthyroid mice; horizontal lines, normal upper limits of each assay; *, significant difference by {chi}2 test.

 
Abs against TSHR were measured with mouse sera. IgG and IgG subclass ELISA were performed with sera obtained 2 and 8 wk after the last immunization, and TSAb and TBIAb were measured with sera obtained 8 wk after the last immunization. Most sera from hyperthyroid mice exhibited positive signals in TSAb assay (Fig. 3C), data compatible with a causative role for TSAb in autoimmune hyperthyroidism (1). In contrast, mice in both groups showed similar Ab titers in TBIAb assays and ELISAs (Fig. 3D and Fig. 4, A and B). IgG1 and IgG2a titers were also similar (Fig. 4, C and D). Thus, there is no difference in the ratios of IgG1/IgG2a between the two groups.



View larger version (28K):
[in this window]
[in a new window]
  		FIGURE 4. Titers of IgG, IgG1, and IgG2a anti-TSHR Abs determined by ELISA. ELISA for IgG, IgG1, and IgG2a of anti-TSHR Abs were performed with sera obtained 2 wk (A and C) and 8 wk (B and D) after the third immunization. Data are the mean ± SD obtained with sera diluted 1/300 (n = 10, 10, and 15 in control, TSHR group, and TSHR plus {alpha}-GalCer group, respectively).

 
The therapeutic efficacy of {alpha}-GalCer was next evaluated. In this experiment, {alpha}-GalCer treatment was initiated 1 wk after the third injection of Ad-TSHR when the effector cells were already fully primed. {alpha}-GalCer (300 µg/kg) was i.p. administered twice a week for 7 wk because the previous study showing successful treatment of type 1 diabetes with {alpha}-GalCer used the higher dose of {alpha}-GalCer (21). Administration of {alpha}-GalCer proved ineffective in curing Graves’ hyperthyroidism; the incidence of disease was essentially the same in the two groups regardless of treatment with {alpha}-GalCer (Fig. 5).



View larger version (20K):
[in this window]
[in a new window]
  		FIGURE 5. T4 levels in mice immunized with Ad-TSHR and treated with vehicle or {alpha}-GalCer in a therapeutic setting. Mice were immunized three times with Ad-TSHR, followed by treatment with vehicle or 300 µg/kg {alpha}-GalCer twice a week for 7 wk. T4 were determined 1 wk (A) and 8 wk (B) after the third immunization with Ad-TSHR. Data are the means of duplicate determinations. {circ}, Euthyroid mice; •, hyperthyroid mice; horizontal lines, the normal upper limits of the assay.

 
Thus, simultaneous administration of {alpha}-GalCer almost completely suppressed Ag-specific splenocyte secretion of IFN-{gamma} and protected Ad-TSHR-immunized mice from Graves’ disease, but {alpha}-GalCer had no therapeutic effect.

Effect of S. mansoni infection on Graves’ disease induction

We used a low dose of cercariae (15/mouse) to infect BALB/c mice, which allowed long term survival, but led to patent, egg-laying infections in 80–90% of mice. Mice with unsuccessful infection were omitted from the study. Ab responses against SWA and SEA after infection with S. mansoni cercariae were determined 3.5 and 7 wk p.i., respectively. Anti-SWA Abs were of IgG1, IgG2a, or both subclasses (Fig. 6A), but anti-SEA Abs were of IgG1 in individual mice (Fig. 6B), indicating mixed Th1 and Th2 Ab responses to SWA and exclusively a Th2 Ab response to SEA.



View larger version (33K):
[in this window]
[in a new window]
  		FIGURE 6. Titers of anti-SWA and SEA Abs determined by ELISA in mice infected with S. mansoni cercariae. ELISA for IgG1 and IgG2a of anti-SWA and SEA Abs were performed with sera obtained 3.5 and 7 wk p.i., respectively. Data are the means of duplicate determinations with 100-fold diluted sera.

 
To evaluate the effect of the sustained Th2 immune deviation by S. mansoni infection on induction of Graves’ disease, mice infected with S. mansoni were subsequently injected with Ad-TSHR three times (8 wk p.i.). Elevated T4 levels were observed in 63% (5 of 8) and 50% (4 of 8) of the TSHR group at the two time points vs 20% (3 of 15) and 7% (1 of 15) in the TSHR plus S. mansoni group (p = 0.042 and p = 0.016, respectively; Fig. 7, A and B).



View larger version (28K):
[in this window]
[in a new window]
  		FIGURE 7. T4, TSAb, and TBIAb values in mice immunized with Ad-TSHR and/or infected with S. mansoni. T4 were determined 2 and 8 wk (A and B), and TSAb and TBIAb were measured 8 wk (C and D) after the third immunization. Data are the means of duplicate determinations in individual mice. {circ}, Hyperthyroid mice; •, euthyroid mice; horizontal lines, the normal upper limits of each assay; *, significant difference by {chi}2 test.

 
TSAb was positive in most hyperthyroid mice (Fig. 7C). TBIAb values were similar between the two groups (Fig. 7D). However, TSHR Ab titers determined by ELISA were slightly, but significantly, lower in the TSHR plus S. mansoni group than in the TSHR group (p = 0.012 and p = 0.022 at the two time points; Fig. 8, A and B), although there was considerable variation between individual mice. IgG1 levels were similar in the two groups, but IgG2a titers were significantly lower in the TSHR plus S. mansoni group than in the TSHR group (p = 0.017 and p = 0.016; Fig. 8, C and D). Thus, IgG1/IgG2a ratios were significantly elevated in the TSHR plus S. mansoni group (p = 0.011 and p = 0.002; Fig. 8, E and F).



View larger version (34K):
[in this window]
[in a new window]
  		FIGURE 8. Titers of IgG, IgG1, and IgG2a anti-TSHR Abs determined by ELISA. ELISAs for IgG, IgG1, and IgG2a of anti-TSHR Abs were performed with sera obtained 2 wk (A, C, and E) and 8 wk (B, D, and F) after the third immunization. Data are the mean ± SD obtained with 300-fold diluted sera (n = 6, 8, and 15 in control, TSHR, and TSHR plus S. mansoni groups). *, Significant difference by Mann-Whitney U test.

 
In contrast to prior infection with S. mansoni, concurrent infection with S. mansoni had little effect on disease induction. Thus, the incidence of disease was similar in the TSHR and TSHR plus S. mansoni groups at the two time points (Fig. 9, A and B). Ab titers measured by TBIAb and ELISA were also similar in the two groups 8 wk after the last immunization (Fig. 9, C and D). Of interest, the ratios of IgG1/IgG2a anti-TSHR Abs were essentially same in the two groups 2 wk after the third injection of Ad-TSHR, but were higher in the TSHR plus S. mansoni group than in the TSHR group 8 wk after the last immunization (p = 0.048) due to the decreased IgG2a titers (p = 0.002; Fig. 9, E–H).



View larger version (37K):
[in this window]
[in a new window]
  		FIGURE 9. T4 and titers of IgG1 and IgG2a anti-TSHR Abs determined by ELISA in mice infected with TSHR alone or simultaneously infected with TSHR and S. mansoni. These values were determined 2 wk (A and E) and 8 wk (B–D and F) after the third immunization. Data are the means of duplicate assays (A–C) or the mean ± SD with 300-fold diluted sera (D–F). {circ}, Euthyroid mice; •, hyperthyroid mice; horizontal lines, the normal upper limits of each assay; *, significant difference by Mann-Whitney U test.

 
Splenocyte secretions of Th1 and Th2 cytokines, IFN-{gamma}, IL-4, and IL-10, were also studied (Fig. 10). Splenocytes from mice immunized with Ad-TSHR after S. mansoni infection exhibited elevated basal levels of IFN-{gamma} (p = 0.006) and impaired production of IFN-{gamma} in response to in vitro stimulation with TSHR-289 (Fig. 10A). These data are reminiscent of our previous data obtained with Ad-IL-4 (3). Splenocytes from Ad-TSHR-immunized mice also produced IL-10 in response to TSHR-289, and prior infection with S. mansoni increased not only the basal, but also Ag-induced, levels of IL-10 (p = 0.004 and p = 0.007), suggesting no effect on the responsiveness of IL-10 to TSHR-289 stimulation (Fig. 10B). In mice concurrently infected with Ad-TSHR and S. mansoni, splenocyte secretion of IFN-{gamma} was intact (Fig. 10C). Thus, the Th2-deviating immune response is associated with the blunt IFN-{gamma} response of splenocytes to stimulation with TSHR Ag. IL-4 was below detectable levels for all condition (data not shown).



View larger version (23K):
[in this window]
[in a new window]
  		FIGURE 10. In vitro secretion of IFN-{gamma} and IL10 from splenocytes of mice infected with Ad-TSHR and/or S. mansoni. Splenocytes were prepared from mice infected with S. mansoni, followed by injection of Ad-TSHR 8 wk p.i. (A and B) or from mice simultaneously infected with Ad-TSHR and S. mansoni (C) and were stimulated with 5 µg/ml TSHR-289 protein for 5 days. IFN-{gamma} (A and C) and IL-10 (B) levels in the culture supernatants were measured by ELISA. Data are the mean ± SD of three mice per group and are expressed as picograms per milliliter. {square}, Splenocytes cultured in the absence of TSHR-289; {blacksquare}, splenocytes cultured in the presence of TSHR-289; *, significant difference by Mann-Whitney U test.

 
To confirm the different effects of S. mansoni eggs and worms, mice were injected with Ad-TSHR in combination with SWA or SEA proteins on days –7, –4, and 0 of each immunization. Injection of SWA and SEA elicited mixed Th1 and Th2 Ab responses and a Th2 Ab response, respectively (Fig. 11A). The incidence of Graves’ hyperthyroidism was significantly lower in the TSHR plus SEA group than in the TSHR plus SWA group 8 wk after the last immunization (p = 0.02; 20% (2 of 10) vs 70% (7 of 10); Fig. 11B).



View larger version (22K):
[in this window]
[in a new window]
  		FIGURE 11. Titers of anti-SWA and SEA Abs and T4 values in mice immunized with Ad-TSHR in combination with SWA or SEA. These values were determined with sera obtained 8 wk after the third immunization. Data are the mean ± SD with 100-fold diluted sera (A) or the mean of duplicate assays (B). {circ}, Euthyroid mice; •, hyperthyroid mice; horizontal line, normal upper limit of T4 assay; *, significant difference by {chi}2 test.

 
Thus, prior infection with S. mansoni suppressed Graves’ hyperthyroidism, IgG2a anti-TSHR Ab titers, and Ag-specific splenocyte secretion of IFN-{gamma}. This protective effect is probably mediated by Ags enriched in soluble egg extracts.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
In this article we studied the effect of sustained Th2 immune deviations induced by S. mansoni infection and {alpha}-GalCer on Graves’ disease using a mouse Graves’ model we have recently established (2). Our results clearly demonstrate that the Th2-dominant immune response against S. mansoni infection and preferential secretion of the Th2 cytokine by repetitive injection of {alpha}-GalCer induced deviation of the anti-TSHR immune response away from Th1. This immune deviation is due to suppression of the Th1 immune response rather than enhancement of the Th2 immune response because prior infection with S. mansoni and {alpha}-GalCer suppressed Ag-specific splenocyte secretion of IFN-{gamma} and/or lowered IgG2a-type TSHR Ab titers. The effect of {alpha}-GalCer on promotion of the Ag-specific Th2 response is controversial; several reports did (20, 21, 25, 26, 27), but the others did not (18, 45), find differentiation of Ag-specific T cells into Th2 cells by {alpha}-GalCer. In contrast, S. mansoni eggs constantly enhance the Th2 immune response to nonparasite Ags (33, 34, 46, 47). The reason(s) for the failure to induce Th2 response to TSHR by S. mansoni is unclear.

We then showed that this immune deviation at the time of Ag priming, not after activation of the TSHR-specific immune response, prevented disease development. Similar data have been obtained in our recent study (3), showing prevention of Graves’ hyperthyroidism by transient expression of IL-4 by adenovirus at the time of Ag presentation. Thus, suppression of the Ag-specific Th1 immune response appears to be crucial to prevent the development of a pathogenic anti-TSHR immune response, but may not be able to revert a fully activated anti-TSHR immune response. This conclusion is consistent with 1) a report by Beaudoin et al. (45) that NKT cells can protect against diabetes induced by passive transfer of naive pathogenic T cells, but cannot prevent diabetes when the pathogenic T cells are fully differentiated into Th1 cells before transfer, in NOD mice; and 2) a report by Boitelle et al. (48) showing suppression of Ag-specific T cell proliferation during the early stage of the primary immune response by parasite infection.

Recent studies show that induction of tolerogenic APCs (22, 49, 50) or regulatory T cells/regulatory cytokines (18, 33, 51, 52) also participates in S. mansoni- and {alpha}-GalCer-mediated amelioration of autoimmune diseases. Furthermore, of interest, Zaccone et al. (38) have recently demonstrated that treatment with SWA and SEA of S. mansoni increased the number of NKT cells in NOD mice. As S. mansoni eggs and worms express a variety of glycoconjugates, including galactosylceramide as mentioned in the introduction (36), the mechanisms for the protective effects of S. mansoni and {alpha}-GalCer may at least partly overlap each other. However, the different patterns of suppression of Ag-specific splenocyte secretion of IFN-{gamma} (Fig. 2 vs Fig. 10) and the different effects on IgG2a Ab titers (Fig. 4 vs Fig. 8) by {alpha}-GalCer and S. mansoni suggest that the effects are not entirely identical. In this regard, it may be worth noting that Ad-IL-4 (3) and S. mansoni both induce partial suppression of Ag-specific splenocyte secretion of IFN-{gamma} and elevation of IgG1/IgG2a ratios of TSHR Abs. Thus, the effects of transiently overexpressed exogenous IL-4 by Ad-IL-4 (3) and more physiological, sustained Th2 immune deviation by S. mansoni are very similar.

Although the titers of anti-TSHR Abs determined by TBIAb assays and ELISAs were largely unaffected, generation of TSAb, i.e., Abs recognizing a particular epitope(s) necessary for TSHR activation, was selectively suppressed. In other words, the immune response to TSHR was still occurring, but development of a pathogenic anti-TSHR response was prevented. We have recently found similar data with Ad-IL-4 (3). These findings are consistent with the previous reports that lymphocyte infiltration of pancreas and CNS could not be completely suppressed by {alpha}-GalCer treatment, NKT cell overexpression, or S. mansoni infection in diabetes and EAE models, albeit less severe (18, 20, 23, 37). In diabetes, lymphocytic infiltration into the pancreas still occurs, but remains largely peri-islet, which is therefore not pathogenic and is unable to mediate {beta} cell destruction.

The present study shows not only splenocyte secretion of IL-10 in response to in vitro stimulation with TSHR Ag, but also elevation of the basal levels of IL-10 by S. mansoni infection. These data may be of interest in terms of the dual functions of IL-10, namely, pro- and anti-inflammatory actions (53). IL-10 is reported to suppress Th1 autoimmune diseases (54, 55) and also to aggravate autoantibody-mediated autoimmune diseases such as lupus and myasthenia gravis (56, 57). IL-10 is reported to be involved in parasite-mediated amelioration of autoimmune diseases; SEA decreased IL-12 production and increased IL-10 secretion from dendritic cells in the presence of LPS (38). These data suggest that IL-10 administration may produce either desirable consequence in Graves’ model, i.e., reduction of Ab production and suppression of disease, or undesirable effect, i.e., exacerbation of disease. Further study will be necessary to address this issue.

It may be worth noting that the number of NKT cells in Graves’ patients is reported to be normal (16), although a causative link between functional defect of NKT cells and development of Graves’ disease is at present unknown in humans. In this regard, it is intriguing that the suppressive effect of {alpha}-GalCer on Graves’ disease is observed in BALB/c mice that have numerically and functionally normal NKT cells (58). Our data suggest that NKT cells may play a crucial role in controlling the pathogenic anti-TSHR immune response in Graves’ disease.

In conclusion, prior infection with S. mansoni and {alpha}-GalCer prevent Graves’ hyperthyroidism in our mouse model, presumably by inhibiting activation of a Th1-type anti-TSHR immune response at the time of Ag priming. These data reinforce the significance of the Th1 immune response in the pathogenesis of Graves’ disease that we have previously proposed (3). Although our animal model may not perfectly mimic Graves’ disease in humans, data supporting the involvement of the Th1 immune response in Graves’ patients, for example, Th1-type TSAb (59), are indeed present.


   Acknowledgments
 
We thank Kirin Brewery (Gunma, Japan) for providing {alpha}-GalCer.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Address correspondence and reprint requests to Dr. Yuji Nagayama, Department of Medical Gene Technology, Atomic Bomb Disease Institute, Graduate School of Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan. E-mail address: nagayama{at}net.nagasaki-u.ac.jp Back

2 Abbreviations used in this paper: TSHR, thyrotropin receptor; TSAb, thyroid-stimulating Ab; Ad-TSHR, adenovirus expressing the human TSHR; p.i., postinfection; {alpha}-GalCer, {alpha}-galactosylceramide; EAE, experimental autoimmune encephalitis; TBIAb, TSH binding-inhibiting Ab; SWA, soluble worm Ag; SEA, soluble egg Ag; T4, thyroxine. Back

Received for publication October 3, 2003. Accepted for publication May 19, 2004.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Rapoport, B., G. D. Chazenbalk, J. C. Jaume, S. M. McLachlan. 1998. The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies. Endocr. Rev. 19:673.[Abstract/Free Full Text]
  2. Nagayama, Y., M. Kita-Furuyama, T. Ando, K. Nakao, H. Mizuguchi, T. Hayakawa, K. Eguchi, M. Niwa. 2002. A novel murine model of Graves’ hyperthyroidism with intramuscular injection of adenovirus expressing the thyrotropin receptor. J. Immunol. 168:2789.[Abstract/Free Full Text]
  3. Nagayama, Y., H. Mizuguchi, T. Hayakawa, M. Niwa, S. M. McLachlan, B. Rapoport. 2003. Prevention of autoantibody-mediated Graves’-like hyperthyroidism in mice by IL-4, a Th2 cytokine. J. Immunol. 170:3522.[Abstract/Free Full Text]
  4. Dogan, R.-N. E., C. Vasu, M. J. Holterman, B. S. Prabhakar. 2003. Absence of Il-4, and not suppression of the Th2 response, prevents development of experimental autoimmune Graves’ disease. J. Immunol. 170:2195.[Abstract/Free Full Text]
  5. Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, et al 1997. CD1d-restricted and TCR-mediated activation of V{alpha}14 NKT cells by glycosylceramides. Science 278:1626.[Abstract/Free Full Text]
  6. Hammond, K. J. L., D. I. Godfrey. 2002. NKT cells: potential targets for autoimmune disease therapy?. Tissue Antigens 59:353.[Medline]
  7. Wilson, S. B., T. L. Delovitch. 2003. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat. Rev. Immunol. 3:211.[Medline]
  8. Singh, N., S. Hong, D. C. Scherer, I. Serizawa, N. Burdin, M. Kronenberg, Y. Koezuka, L. V. Kaer. 1999. Activation of NK T cells by CD1d and {alpha}-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. J. Immunol. 163:2373.[Abstract/Free Full Text]
  9. Burdin, N., L. Brossay, M. Kronenberg. 1999. Immunization with {alpha}-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis. Eur. J. Immunol. 29:2014.[Medline]
  10. Yoshimoto, T., A. Bendelac, J. Hu-Li, W. E. Paul. 1995. Defective IgE production by SJL mice is linked to the absence of CD4+, NK1.1+ T cells that promptly produce interleukin-4. Proc. Natl. Acad. Sci. USA 92:11931.[Abstract/Free Full Text]
  11. Sumida, T., A. Sakamoto, H. Murata, Y. Makino, H. Takahashi, S. Yoshida, K. Nishioka, I. Iwamoto, M. Taniguchi. 1995. Selective reduction of T cells bearing invariant V{alpha}24J{alpha}Q antigen receptor in patients with systemic sclerosis. J. Exp. Med. 182:1163.[Abstract/Free Full Text]
  12. Gombert, J. M., A. Herbelin, E. Tancrede-Bohin, M. Dy, C. Carnaud, J. F. Bach. 1996. Early quantitative and functional deficiency of NK1+-like thymocytes in the NOD mouse. Eur. J. Immunol. 26:2989.[Medline]
  13. Hammond, K. J. L., L. D. Poulton, L. J. Palmisano, P. A. Silveira, D. I. Godfrey, A. G. Baxter. 1998. {alpha}/{beta}-T cell receptor (TCR)+CD4–CD8– (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J. Exp. Med. 187:1047.[Abstract/Free Full Text]
  14. Wilson, S. B., S. C. Kent, K. T. Patton, T. Orban, R. A. Jackson, M. Exley, S. Porcelli, D. A. Schatz, M. A. Atkinson, S. P. Balk, et al 1998. Extreme Th1 bias of invariant V{alpha}24J{alpha}Q T cells in type 1 diabetes. Nature 391:177.[Medline]
  15. Illes, Z., T. Kondo, J. Newcombe, N. Oka, T. Tabira, T. Yamamura. 2000. Differential expression of NK T cell V{alpha}24J{alpha}Q invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelimating polyneuropathy. J. Immunol. 164:4375.[Abstract/Free Full Text]
  16. van der Vliet, H. J. J., B. M. E. von Blomberg, N. Nishi, M. Reijm, A. E. Voskuyl, A. A. van Bodegraven, C. H. Polman, T. Rustemeyer, P. Lips, A. J. M. van den Eertwegh, et al 2001. Circulating V{alpha}24+ V{beta}11+ NKT cell number s are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin. Immunol. 100:144.[Medline]
  17. Lehuen, A., O. Lantz, L. Beaudoin, V. Laloux, C. Carnaud, A. Bendelac, J.-F. Bach, R. C. Monteiro. 1998. Overexpression of natural killer T cells protects V{alpha}14-J{alpha}281 transgenic nonobese diabetic mice against diabetes. J. Exp. Med. 188:1831.[Abstract/Free Full Text]
  18. Mars, L. T., V. Laloux, K. Goude, S. Desbois, A. Saoudi, L. van Kaer, H. Lessmann, A. Herbelin, A. Lehuen, R. S. Liblau. 2002. V{alpha}14-J{alpha}281 NKT cells naturally regulate experimental autoimmune encephalitis in nonobese diabetic mice. J. Immunol. 168:6007.[Abstract/Free Full Text]
  19. Saubermann, L. J., P. Beck, Y. P. De Jong, R. S. Pitman, M. S. Ryan, H. S. Kim, M. Exley, S. Snapper, S. P. Balk, S. J. Hagen, et al 2000. Activation of natural killer T cells by {alpha}-galactosylceramide in the presence of CD1d provided protection against colitis. Gastroenterology 119:119.[Medline]
  20. Hong, S., M. T. Wilson, I. Serizawa, L. Wu, N. Singh, O. V. Naidenko, T. Miura, T. Haba, D. C. Scherer, J. Wei, et al 2001. The natural killer T-cell ligand {alpha}-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat. Med. 7:1052.[Medline]
  21. Sharif, S., G. A. Arreaza, P. Zucker, Q.-S. Mi, J. Sondhi, O. V. Naidenko, M. Kronenberg, Y. Koezuka, T. L. Delovitch. 2001. Activation of natural killer T cells by {alpha}-galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes. Nat. Med. 7:1057.[Medline]
  22. Naumov, Y., K. Bahjat, R. Gausling, R. Abraham, M. A. Exley, Y. Koezuka, S. B. Balk, J. L. Stromingle, M. Clare-Salzer, S. B. Wilson. 2001. Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Proc. Natl. Acad. Sci. USA 98:13838.[Abstract/Free Full Text]
  23. Wang, B., Y.-B. Geng, C.-R. Wang. 2001. CD1-restricted NK T cells protect non-obese diabetic mice form developing diabetes. J. Exp. Med. 194:313.[Abstract/Free Full Text]
  24. Pal, E., T. Tabira, T. Kawano, M. Taniguchi, S. Miyake, T. Yamamura. 2001. Costimulation-dependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of V{alpha}14 NKT cells. J. Immunol. 166:662.[Abstract/Free Full Text]
  25. Singh, A. K., M. T. Wilson, S. Hong, D. Olivares-Villagomez, C. Du, A. K. Stanic, S. Joyce, S. Sriram, Y. Koezuka, L. V. Kaer. 2001. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J. Exp. Med. 194:1801.[Abstract/Free Full Text]
  26. Jahng, A. W., I. Maricic, B. Pedersen, N. Burdin, O. Naidenko, M. Kronenberg, Y. Koezuka, V. Kumar. 2001. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalitis. J. Exp. Med. 194:1789.[Abstract/Free Full Text]
  27. Furlan, R., A. Bergami, D. Cantarella, E. Brambilla, M. Taniguchi, P. Dellabona, G. Casorati, G. Martino. 2003. Activation of invariant NKT cells by {alpha}-GalCer administration protects mice from MOG35–55-induced EAE: critical roles for administration route and IFN-{gamma}. Eur. J. Immunol. 33:1830.[Medline]
  28. Shi, F. D., M. Flodstrom, B. Balasa, S. H. Kim, K. van Gunst, J. L. Strominger, S. B. Wilson, N. Sarvetnick. 2001. Germ-line deletion of the CD1d locus exacerbates diabetes in the NOD mice. Proc. Natl. Acad. Sci. USA 98:6777.[Abstract/Free Full Text]
  29. Sewell, D. L., E. K. Reinke, L. H. Hogan, M. Sandor, Z. Fabry. 2002. Immunoregulation of CNS autoimmunity by helminth and mycobacterial infections. Immunol. Lett. 82:101.[Medline]
  30. Pearce, E. J., A. L. Flamme, E. Sabin, L. R. Brunet. 1998. The initiation and function of Th2 responses during infection with Schistosoma mansoni. S. Gupta, and R. Ahmed, and A. Sher, eds. Mechanisms and Lymphocyte Activation and Immune Regulation, Vol. VII: Molecular Determinants of Microbial Immunity 67. Plenum Press, New York.
  31. Grzych, J.-M., E. Pearce, A. Cheever, Z. A. Caulada, P. Casper, S. Heiny, F. Lewis, A. Sher. 1991. Egg deposition is the major stimulus for the production of Th2 cytokines in murine Schistosomiasis mansoni. J. Immunol. 146:1322.[Abstract]
  32. Pearce, E. J., P. Casper, J.-M. Grzych, F. A. Lewis, A. Sher. 1991. Downregulation of Th1 cytokine production accompanies induction of Th2 responses by a parasitic helminth, Schistosoma mansoni. J. Exp. Med. 173:159.[Abstract/Free Full Text]
  33. Kullberg, M. C., E. J. Pearce, S. E. Hieny, A. Sher, J. A. Berzofsky. 1992. Infection with Schistosoma mansoni alters Th1/Th2 cytokine responses to a non-parasite antigen. J. Immunol. 148:3264.[Abstract]
  34. Actor, J. K., M. A. Marshall, I. A. Eltoum, R. M. L. Buller, J. A. Berzofsky, A. Sher. 1994. Increased susceptibility of mice infected with Schistosoma mansoni to recombinant vaccinia virus: association of viral persistence with egg granuloma formation. Eur. J. Immunol. 24:3050.[Medline]
  35. Curry, A. J., K. J. Else, F. Jones, A. Bancroft, R. K. Grencis, D. W. Dunne. 1995. Evidence that cytokine-mediated immune interactions induced by Schistosoma mansoni alter disease outcome in mice concurrently infected with Trichuris muris. J. Exp. Med. 181:769.[Abstract/Free Full Text]
  36. Makaaru, C. K., R. T. Damian, D. F. Smith, R. D. Cummings. 1992. The human blood fluke Schistosoma mansoni synthesizes a novel type of glycosphingolipids. J. Biol. Chem. 167:2251.
  37. Cooke, A., P. Tonks, F. M. Jones, H. O’Shea, P. Hutchings, A. J. Fulford, D. W. Dunne. 1999. Infection with Schistosoma mansoni prevents insulin dependent diabetes mellitus in non-obese diabetic mice. Parasitol. Immunol. 21:169.[Medline]
  38. Zaccone, P., Z. Fehervari, F. M. Jones, S. Sidobre, M. Kronenberg, D. W. Dunne, A. Cooke. 2003. Schistosoma mansoni antigens modulate the activity of the innate immune response and prevent onset of type 1 diabetes. Eur. J. Immunol. 33:1439.[Medline]
  39. Sewell., D., Z. Qing, E. Reinke, D. Elliot, J. Weinstock, M. Sandor, Z. Fabry. 2003. Immunomodulation of experimental autoimmune encephalitis by helminth ova immunization. Int. Immunol. 15:59.[Abstract/Free Full Text]
  40. Mattsson, L., P. Larsson, H. Erlandsson-Harris, L. Klareskog, R. A. Harris. 2000. Parasite-mediated down-regulation of collagen-induced arthritis (CIA) in DA rats. Clin. Exp. Immunol. 122:477.[Medline]
  41. Matsumura, K., Y. Mitsui, K. Sato, M. Sakamoto, Y. Aoki. 1991. Schistosoma mansoni: possible involvement of protein kinase C in linoleic acid-induced proteolytic enzyme release from cercariae. Exp. Parasitol. 72:311.[Medline]
  42. Boros, D. L., K. S. Warren. 1970. Delayed hypersensitivity-type granuloma formation and dermal reaction induced and elicited by a soluble factor isolated from Schistosoma mansoni eggs. J. Exp. Med. 132:488.[Abstract]
  43. Pearce, E. J., S. L. James, S. Hieny, D. E. Lanar, A. Sher. 1988. Induction of protective immunity against Schistosoma mansoni by vaccination with schistosome paramyosin (Sm97), a nonsurface parasite antigen. Proc. Natl. Acad. Sci. USA 85:5678.[Abstract/Free Full Text]
  44. Chazenbalk, G. D., S. M. McLachlan, P. Pichurin, B. Rapoport. 2001. A "prion-like" shift between two conformational forms of a recombinant thyrotropin receptor A subunit module: purification and stabilization using chemical chaperones of the form reactive with Graves’ autoantibodies. J. Clin. Endocrinol. Metab. 86:1287.[Abstract/Free Full Text]
  45. Beaudoin, L., V. Laloux, J. Novak, B. Lucas, A. Lehuen. 2002. NKT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specific for pancreatic {beta} cells. Immunity 17:725.[Medline]
  46. Paterson, J. C. M., P. Garside, M. W. Kennedy, C. E. Lawrence. 2002. Modulation of a heterologous immune response by the products of Ascaris suum. Infect. Immun. 70:6058.[Abstract/Free Full Text]
  47. Pearlman, E., J. W. Kazura, F. E. Hazlett., Jr, W. H. Boom. 1993. Modulation of murine cytokine responses to mycobacterial antigens by helminth-induced T helper 2 cell response. J. Immunol. 151:4857.[Abstract]
  48. Boitelle, A., H. E. Scales, C. D. Lorenzo, E. Devaney, M. W. Kennedy, P. Garside, C. E. Lawrence. 2003. Investigating the impact of helminth products on immune responsiveness using a TCR transgenic adoptive transfer system. J. Immunol. 171:447.[Abstract/Free Full Text]
  49. Allen, J. E., A. S. MacDonald. 1998. Profound suppression of cellular proliferation mediated by the secretions of nematodes. Parasite Immunol. 20:241.[Medline]
  50. Osborne, J., E. Devaney. 1999. Interleukin-10 and antigen-presenting cells actively suppress Th1 cells in BALB/c mice infected with the filarial parasite Brugia pahangi. Infect. Immun. 67:1599.[Abstract/Free Full Text]
  51. Doetze, A., J. Satoguina, G. Burchard, T. Rau, C. Loliger, B. Fleischer, A. Hoerauf. 2000. Antigen-specific cellular hyporesponsiveness in a chronic human helminth infection is mediated by Th3/Tr1-type cytokines IL-10 and transforming growth factor-{beta} but not by Th1 to Th2-type shift. Int. Immunol. 12:623.[Abstract/Free Full Text]
  52. Satoguina, J., M. Mempel, J. Larbi, M. Badusche, C. Loliger, O. Adijei, G. Gachelin, B. Fleischer, A. Hoerauf. 2002. Antigen-specific T regulatory-1 cells are associated with immunosuppression in a chronic helminth infection (onchocerciasis). Microbes Infect. 4:1291.[Medline]
  53. Howard, M., A. O’Garra. 1992. Biological properties of IL-10. Immunol. Today 13:198.[Medline]
  54. Pennline, K. J., E. Roque-Gaffney, M. Monahan. 1994. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mice. Clin. Immunol. Immunopathol. 71:169.[Medline]
  55. Rott, O., B. Fleischer, E. Cash. 1994. Interleukin-10 prevents experimental allergic encephalitis in rats. Eur. J. Immunol. 24:1434.[Medline]
  56. Zhang, G.-X., B.-G. Xiao, L.-Y. Yu, P. H. van der Meide, H. Link. 2001. Interleukin-10 aggravates experimental autoimmune myasthenia gravis through inducing Th2 and B cell responses to AChR. J. Neuroimmunol. 113:10.[Medline]
  57. Ishida, H., T. Muchamuel, S. Sakaguchi, S. Andrade, S. Menon, M. Howard. 1994. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J. Exp. Med. 179:305.[Abstract/Free Full Text]
  58. Hammond, K. J. L., D. G. Pellicci, L. D. Poulton, O. V. Naidenko, A. A. Scalzo, A. G. Baxter, D. I. Godfrey. 2001. CD1d-restricted NKT cells: an interstrain comparison. J. Immunol. 167:1164.[Abstract/Free Full Text]
  59. Weetman, A. P., M. E. Yateman, P. A. Ealey, C. M. Black, C. B. Reimer, R. C. Williams, Jr, B. Shine, N. J. Marshall. 1990. Thyroid-stimulating antibody activity between different immunoglobulin G subclasses. J. Clin. Invest. 86:723.



This article has been cited by other articles:


Home page
 EndocrinologyHome page
A. V. Misharin, Y. Nagayama, H. A. Aliesky, Y. Mizutori, B. Rapoport, and S. M. McLachlan
Attenuation of Induced Hyperthyroidism in Mice by Pretreatment with Thyrotropin Receptor Protein: Deviation of Thyroid-Stimulating to Nonfunctional Antibodies
Endocrinology, August 1, 2009; 150(8): 3944 - 3952.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
L. E. Bazzone, P. M. Smith, L. I. Rutitzky, M. G. Shainheit, J. F. Urban, T. Setiawan, A. M. Blum, J. V. Weinstock, and M. J. Stadecker
Coinfection with the Intestinal Nematode Heligmosomoides polygyrus Markedly Reduces Hepatic Egg-Induced Immunopathology and Proinflammatory Cytokines in Mouse Models of Severe Schistosomiasis
Infect. Immun., November 1, 2008; 76(11): 5164 - 5172.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
O. Saitoh, N. Abiru, M. Nakahara, and Y. Nagayama
CD8+CD122+ T Cells, a Newly Identified Regulatory T Subset, Negatively Regulate Graves' Hyperthyroidism in a Murine Model
Endocrinology, December 1, 2007; 148(12): 6040 - 6046.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
T. Kaneda, A. Honda, A. Hakozaki, T. Fuse, A. Muto, and T. Yoshida
An Improved Graves' Disease Model Established by Using in Vivo Electroporation Exhibited Long-Term Immunity to Hyperthyroidism in BALB/c Mice
Endocrinology, May 1, 2007; 148(5): 2335 - 2344.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
O. Saitoh and Y. Nagayama
Regulation of Graves' Hyperthyroidism with Naturally Occurring CD4+CD25+ Regulatory T Cells in a Mouse Model
Endocrinology, May 1, 2006; 147(5): 2417 - 2422.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
G Aust, K Krohn, N G Morgenthaler, S Schroder, A Schutz, J Edelmann, and E Brylla
Graves' disease and Hashimoto's thyroiditis in monozygotic twins: case study as well as transcriptomic and immunohistological analysis of thyroid tissues
Eur. J. Endocrinol., January 1, 2006; 154(1): 13 - 20.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
S. M. McLachlan, Y. Nagayama, and B. Rapoport
Insight into Graves' Hyperthyroidism from Animal Models
Endocr. Rev., October 1, 2005; 26(6): 800 - 832.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
G Aust, M Kamprad, P Lamesch, and E Schmucking
CXCR6 within T-helper (Th) and T-cytotoxic (Tc) type 1 lymphocytes in Graves' disease (GD)
Eur. J. Endocrinol., April 1, 2005; 152(4): 635 - 643.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Roura-Mir, M. Catalfamo, T.-Y. Cheng, E. Marqusee, G. S. Besra, D. Jaraquemada, and D. B. Moody
CD1a and CD1c Activate Intrathyroidal T Cells during Graves' Disease and Hashimoto's Thyroiditis
J. Immunol., March 15, 2005; 174(6): 3773 - 3780.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
H. Y. Kim, H. J. Kim, H. S. Min, S. Kim, W. S. Park, S. H. Park, and D. H. Chung
NKT cells promote antibody-induced joint inflammation by suppressing transforming growth factor {beta}1 production
J. Exp. Med., January 3, 2005; 201(1): 41 - 47.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
Y. Nagayama, S. M. McLachlan, B. Rapoport, and K. Oishi
Graves' Hyperthyroidism and the Hygiene Hypothesis in a Mouse Model
Endocrinology, November 1, 2004; 145(11): 5075 - 5079.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nagayama, Y.
Right arrow Articles by Rapoport, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nagayama, Y.
Right arrow Articles by Rapoport, B.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS